An in-depth look to BIOGEND THERAPEUTICS CO LTD operating, investing, and financing activities

6733 free cash flow for Q2 24 is -28.6 M TWD. For 2023, 6733 free cash flow was -164.76 M TWD and operating cash flow was -138.72 M TWD.